Brief reports
Do elderly systolic heart failure patients benefit from beta blockers to the same extent as the non-elderly? Meta-analysis of >12,000 patients in large-scale clinical trials

https://doi.org/10.1016/j.amjcard.2004.11.052Get rights and content

A meta-analysis of all-cause mortality data involving elderly and non-elderly chronic heart failure patients from 5 completed β-blocker trials revealed that elderly and non-elderly chronic heart failure patients derived considerable prognostic benefit from β-blocker therapy without a statistically significant difference in mortality reduction between the 2 groups.

References (12)

  • S.G. Thompson et al.

    Can meta-analyses be trusted?

    Lancet

    (1991)
  • M.D. Flather et al.

    Strengths and limitations of meta-analysis: larger studies may be more reliable

    Control Clin Trials

    (1997)
  • A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure

    N Engl J Med

    (2001)
  • M. Packer et al.

    The effect of carvedilol on morbidity and mortality in patients with chronic heart failure

    N Engl J Med

    (1996)
  • The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial

    Lancet

    (1999)
  • M. Packer et al.

    Effect of carvedilol on survival in severe chronic heart failure

    N Engl J Med

    (2001)
There are more references available in the full text version of this article.

Cited by (90)

  • Pharmacotherapy Use in Older Patients With Heart Failure and Reduced Ejection Fraction After a Skilled Nursing Facility Stay

    2017, Journal of Cardiac Failure
    Citation Excerpt :

    Advanced age, particularly ≥85 years, was associated with less EBBB use, though not any β-blocker use, which is consistent with a previous report.32 Although the benefits of EBBBs, like ACEIs/ARBs, are also less certain in older age groups, a meta-analysis of >12,000 clinical trial subjects which included elderly patients showed no difference in mortality benefit between elderly and nonelderly HF patients treated with EBBBs.33 Because the effects of EBBBs on day-to-day quality of life is variable,10 if clinicians' uncertainty about the risk-benefit ratios of EBBBs increases with advanced age, we may be observing appropriate clinical judgment rather than undertreatment.

  • Chronic heart failure in the elderly patient

    2015, Revista Espanola de Geriatria y Gerontologia
View all citing articles on Scopus
View full text